Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist.


Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
05 2019
Historique:
received: 18 10 2018
pubmed: 23 3 2019
medline: 11 4 2020
entrez: 23 3 2019
Statut: ppublish

Résumé

A substantial proportion of patients with suboptimal control of their type 2 diabetes experience delays in treatment intensification. Additionally, patients often experience overuse of basal insulin, commonly referred to as "over-basalization," whereby basal insulin continues to be uptitrated in order to meet targets, when addition of a mealtime bolus insulin dose may be a more appropriate option. In order to overcome these challenges, there is a need to develop the capacity of allied healthcare professionals to provide appropriate support to these patients, such as during initiation or titration of basal insulin. Pharmacists play an integral role in healthcare delivery, with patients seeing their pharmacist, on average, seven times more often than their primary care physician. This places pharmacists in a unique position to provide diabetes education and care, which may help patients avoid clinical inertia. Nevertheless, the management of the disease with basal insulin is becoming increasingly complex, with growing numbers of treatment options (such as recent second-generation longer-acting basal insulin formulations) and frequently updated titration algorithms. The two most common titration schedules specify either increasing doses by a set amount every 2-3 days or a treat-to-target strategy. Neither schedule has been shown to be superior, and the decision to use one or the other should be based on a discussion between the clinician and patient after assessment of mental and physical acumen, comfort of both parties, and follow-up plans. This review article discusses basal insulin therapy options and titration algorithms from the unique perspective of the pharmacist in order to help ensure that optimal antidiabetes therapy is initiated, appropriately titrated, and maintained.Funding: Sanofi US, Inc.

Identifiants

pubmed: 30900198
doi: 10.1007/s12325-019-00907-8
pii: 10.1007/s12325-019-00907-8
pmc: PMC6824379
doi:

Substances chimiques

Blood Glucose 0
Hypoglycemic Agents 0
Insulin 0

Banques de données

figshare
['10.6084/m9.figshare.7701077']

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

1031-1051

Références

Diabetes Ther. 2014 Dec;5(2):347-54
pubmed: 25113408
Diabetes Obes Metab. 2013 Aug;15(8):729-36
pubmed: 23421331
Am J Health Syst Pharm. 2010 Jan 1;67(1):42-8
pubmed: 20044368
Int J Clin Pract. 2016 Jan;70(1):56-65
pubmed: 26566714
Endocr Pract. 2018 Jan;24(1):91-120
pubmed: 29368965
Diabetes Care. 2013 Apr;36(4):858-64
pubmed: 23340894
Diabetologia. 2012 Jun;55(6):1577-96
pubmed: 22526604
Diabetes Care. 2013 Nov;36(11):3411-7
pubmed: 23877982
Diabetes Obes Metab. 2015 Aug;17(8):734-41
pubmed: 25931141
Diabetes Res Clin Pract. 2014 Apr;104(1):1-52
pubmed: 24508150
Diabetes Metab Syndr Obes. 2015 Oct 01;8:483-93
pubmed: 26457056
Diabetes Res Clin Pract. 2011 May;92(2):145-52
pubmed: 20961643
Pharmacotherapy. 2016 Mar;36(3):348-56
pubmed: 26877253
Diabetes Obes Metab. 2012 Oct;14(10):944-50
pubmed: 22726241
Diabetes. 2004 Jun;53(6):1614-20
pubmed: 15161770
Cochrane Database Syst Rev. 2016 Nov 22;11:CD011227
pubmed: 27873322
Diabetes Obes Metab. 2007 Nov;9(6):902-13
pubmed: 17924873
Diabetes Care. 2006 Jan;29(1):1-8
pubmed: 16373887
Diabetes Care. 1999 Mar;22(3):394-8
pubmed: 10097916
Lancet Diabetes Endocrinol. 2013 Oct;1(2):123-31
pubmed: 24622318
Diabetes Obes Metab. 2016 Apr;18(4):425-9
pubmed: 26749289
Clin Pharmacokinet. 2014 Sep;53(9):787-800
pubmed: 25179915
Diabetes Care. 2006 Jun;29(6):1269-74
pubmed: 16732007
J Clin Pharm Ther. 2011 Oct;36(5):602-13
pubmed: 21143256
Diabetes Care. 2005 Nov;28(11):2673-9
pubmed: 16249538
JAMA. 2017 Jul 4;318(1):45-56
pubmed: 28672317
Diabetologia. 2006 Mar;49(3):442-51
pubmed: 16456680
Diabetes Care. 2005 May;28(5):1107-12
pubmed: 15855574
Am J Health Syst Pharm. 2006 Jul 15;63(14):1325-31
pubmed: 16809752
Diabetes Obes Metab. 2015 Jan;17(1):15-22
pubmed: 24957785
Adv Ther. 2013 Jun;30(6):607-22
pubmed: 23812875
Ann Pharmacother. 2012 Jan;46(1):29-34
pubmed: 22202497
Diabetes Obes Metab. 2016 Apr;18(4):401-9
pubmed: 26743666
Diabetes Care. 2013 Sep;36(9):2536-42
pubmed: 23715753
Clin Drug Investig. 2013 Jul;33(7):515-21
pubmed: 23749405
Diabetes Obes Metab. 2015 Sep;17(9):859-67
pubmed: 25929311
Am J Health Syst Pharm. 2016 Sep 15;73(18):1406-15
pubmed: 27605319
Pharmacotherapy. 2006 Feb;26(2):248-53
pubmed: 16466329
Clin Ther. 2006 Oct;28(10):1569-81
pubmed: 17157113
Lancet. 1999 Nov 6;354(9190):1604-7
pubmed: 10560676
Diabetes Care. 2018 Oct;41(10):2147-2154
pubmed: 30104294
Diabetes Care. 2005 Jun;28(6):1282-8
pubmed: 15920040
Int J Clin Pract. 2014 Mar;68(3):304-13
pubmed: 24471814
BMJ Open. 2013 Sep 24;3(9):e003154
pubmed: 24068762
Diabetes Obes Metab. 2015 Apr;17(4):386-94
pubmed: 25641260
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
Diabetes Obes Metab. 2007 Sep;9(5):648-59
pubmed: 17645556
Diabetes Care. 2003 Nov;26(11):3080-6
pubmed: 14578243
J Diabetes Sci Technol. 2012 Mar 01;6(2):412-20
pubmed: 22538155
Clin Med Res. 2008 Sep;6(2):54-67
pubmed: 18801953
Diabetes Care. 2013 Aug;36(8):2271-9
pubmed: 23418368
Cleve Clin J Med. 2016 May;83(5 Suppl 1):S27-33
pubmed: 27176680
J Diabetes Sci Technol. 2015 May 13;9(6):1342-5
pubmed: 25972281
Diabetologia. 2008 Mar;51(3):408-16
pubmed: 18204830
Diabetes Care. 2012 Dec;35(12):2464-71
pubmed: 23043166
Cochrane Database Syst Rev. 2011 Jul 06;(7):CD006383
pubmed: 21735405
Diabet Med. 2012 May;29(5):682-9
pubmed: 22313123
J Diabetes. 2014 Mar;6(2):176-83
pubmed: 23931125
Ann Pharmacother. 2016 Dec;50(12):1023-1027
pubmed: 27497068
J Am Pharm Assoc (2003). 2012;52(6):e266-72
pubmed: 23229989
J Diabetes Investig. 2013 Nov 27;4(6):605-12
pubmed: 24843715
J Diabetes Complications. 2015 Aug;29(6):838-45
pubmed: 25981123
Ann Pharmacother. 2018 Feb;52(2):198-211
pubmed: 28948839
Diabetes Care. 2015 Apr;38(4):637-43
pubmed: 25150159
Diabetes Obes Metab. 2009 Jun;11(6):623-31
pubmed: 19515182
Diabetes Metab. 2018 Feb;44(1):15-21
pubmed: 29153485
Diabet Med. 2016 Apr;33(4):478-87
pubmed: 26484727

Auteurs

Dhiren Patel (D)

School of Pharmacy, MCPHS University, Boston, MA, USA. dhiren.patel1@mcphs.edu.

Curtis Triplitt (C)

Texas Diabetes Institute, University of Texas Health Science Center, San Antonio, TX, USA.

Jennifer Trujillo (J)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH